

In the News: Congratulations to the following awardees!!



Gregory Homish, Professor and Chair of Community Health and Health Behavior, is Co-PI on a continuation award (Co-PI: Ken Leonard, Psychiatry) from the National Institute on Alcohol Abuse and Alcoholism/NIH, for the T32-training grant entitled *Research Training on Alcohol Etiology and Treatment*. Established in 2000, the interdisciplinary training program provides postdoctoral and predoctoral trainees with research training on the etiology and treatment of alcohol problems.



Lucia Leone, Associate Professor of Community Health and Health Behavior, received an award from UB's Office of International Education for the research project entitled, *Food Access and Diet in Low-income Communities in Panama*. During the 2022-2023 academic year, Dr. Leone will take a sabbatical to Panama to replicate her previous community-based research conducted in the U.S., with the goal of identifying factors that affect food access and diet in lower-income communities in Panama.

Dr. Leone also received a Diversity Supplement from the National Cancer Institute/NIH for her R01 entitled, *Effectiveness and Implementation of a Research Tested Mobile Produce Market Designed to Improve Diet in Underserved Communities*. This administrative supplement will support Christina Kasprzak, Postdoctoral Associate, with her development of research and professional skills as related to her with postdoctoral training.



Katarzyna Kordas, Associate Professor of Epidemiology and Environmental Health, received an award from UB's Office of International Education for the research project entitled, *Food Supply Contamination and Childhood Exposure to Toxic Elements: A Comparative Study between Uruguay and the US*. The project will test toxic element levels in a market basket of commonly consumed foods in Montevideo, Uruguay, estimate exposure levels among school-age children, and compare exposures to similarly-aged children in the US.



Vijaya Prakash Krishnan Muthaiah, Assistant Professor of Rehabilitation Science, received a new award from UB's CTSI Center for Biomedical Imaging Pilot Study program for the project entitled, *Mapping of Metabolic Profiles with the Structural Connectivity of the Auditory Pathway in Blast Traumatic Brain Injury*. The project will use spectrum analysis of chemical metabolites in Magnetic Resonance Spectroscopy to shed light on the pathomechanism of blast TBI and blast-induced tinnitus as an imbalance of excitatory-inhibitory network in auditory and non-auditory structures. The results will establish a biomarker for disease severity, testing the efficacy of candidate drugs for TBI and tinnitus therapy and potential toxicity.



Kimberly Naus, Director of CAT Clients Services, is PI on a renewal award from the NYS Office of Children and Family Services for the project entitled, *Equipment Loan Closet*. The program enables clients with visual impairments to enhance their educational and vocational goals while being provided with assistive hardware and software.




Tia Palermo, Associate Professor of Epidemiology and Environmental Health, is PI on a new award from the International Food Policy Research Institute/Wellspring Philanthropic Fund for the research project entitled, *Cash Transfer and Intimate Partner Violence (CT & IPV) Research Collaborative*. The overall long-term goal of the collaborative is to advance the research agenda linking cash transfers and IPV in order to effectively leverage cash programming for IPV prevention among poor and vulnerable women in low- and middle-income counties (LMICs). Activities include defining and contributing evidence to address knowledge gaps, aggregating

evidence, bringing together researchers and practitioners, and disseminating research findings via channels that maximize evidence uptake for policy.



Riana Pryor, Assistant Professor of Exercise and Nutrition Science, is PI on a continuation award from the Centers for Disease Control and Prevention for the research project entitled, *Short- and Long-term Health Consequences of Workers During Consecutive Days of Heat Stress*. The proposed study will provide data to inform NIOSH’s recommendations for fatigue mitigation and to meet long-term health needs of workers during consecutive days of heat stress.



Meng Wang, Assistant Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Institute of Environmental Health Sciences/NIH for the research project entitled, *Air Pollution, Coronary Events, Atherosclerotic Progression in a Susceptible Population*. The study will continue to examine whether exposure to air pollutants alter coronary biological process, accelerate disease progression, and contribute to coronary heart disease in 3500 patients with atherosclerosis in Beijing. **Lina Mu**, Associate Professor of Epidemiology and Environmental Health, and **Guan Yu**, Assistant Professor of Biostatistics, are Co-Investigators.



Gregory Wilding, Professor and Chair of Biostatistics, is Co-I on two continuation awards. The first is from the National Institute of Allergy and Infectious Diseases/NIH (PI: Jonathan Lovell, Biomedical Engineering) for the project entitled, *Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria Vaccine*. The project will continue to develop a vaccine that will block the transmission of malaria by focusing the immune response towards the same target epitope of a potent monoclonal.

The second, from the National Institute of Nursing Research/NIH (PI: Grace Dean, Nursing), is entitled, *Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors*. The study will continue to test a self-management behavioral intervention for cancer survivors with insomnia in order to reduce disease burden, improve well-being, strengthen self-determination and participation in health care, and prevent illness and complications.

In This Issue

In the News: Congratulations to the Following Awardees 1

Grant Clinic 2

NIH Funding Opportunities

Limited Submissions 4

Request for Applications (RFA) 4

Program Announcements Reviews in an Institute (PAR) 8

Program Announcements (PA)

UB Funding Opportunities 9

Individual Actions for Sustainability 10

Grant Clinic

[How to Create a Grants.gov Account and Link to a Login.gov Account](#)

Faculty who have not yet linked their Grant.gov account to their Login.gov account or have questions about creating and linking the accounts may find the blog post on Grants.gov helpful.

GENERAL NOTICE

[NOT-OD-22-138](#) – The NIH Office of Disease Prevention (ODP) Announces the Pathways to Prevention Workshop: Nutrition as Prevention for Improved Cancer Health Outcomes.

July 26–28, 2022, Online Only. [Register to Attend](#)

The NIH is hosting the virtual Pathways to Prevention Workshop: [Nutrition as Prevention for Improved Cancer Health Outcomes](#) to assess the scientific evidence on how nutritional interventions affect cancer health outcomes and identify research gaps.

NOTICE OF INTENT TO PUBLISH

[NOT-HD-22-022](#) – Centers of Excellence in Maternal Health Research; anticipated release date July 25, 2022; expected due date: November 30, 2022

[NOT-HD-22-018](#) - Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network Clinical Research Centers; anticipated release date July 26, 2022; expected due date November 30, 2022.

NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-DA-22-004](#)– Epidemiology of Drug Abuse

NIDA encourages applications that enhance the understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, misuse and addiction across individuals, families, communities, and diverse population groups. **For funding consideration, applicants must include NOT-DA-22-004 in box 4B of the SF424 R&R form.** This notice applies to due dates 6/5/22-9/8/25.

[NOT-AA-22-012](#) – Research on Alcohol and Coronavirus Disease (COVID-19) within the Mission

NIAAA will support research on risks and outcomes associated with alcohol consumption, SARS-CoV2 infection, and the COVID-19 pandemic in the general population among underserved populations. **For funding consideration, applicants must include NOT-AA-22-012 in box 4B of the SF242 R&R form.** This notice applies to due dates through March 5, 2024.

[NOT-CA-22-085](#) – Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer

The purpose of this NOSI is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms. Studies that integrate expertise from multiple disciplines, incorporate state-of-the-art, human-relevant models (e.g., organoid or patient-derived xenograft models) and utilize advanced technologies and methods are strongly encouraged. **Applicants must include NOT-CA-22-085 in Box 4B of the SF424 R&R form.** This notice applies to due dates through May 8, 2027.

[NOT-ES-22-006](#) – Climate Change and Health

The NIEHS is leading an NIH-wide [Climate Change and Health Initiative \(CCHI\)](#) with the goals of: reducing the health threats posed by climate change, improving the health of people who are at increased risk from or disparately affected by climate change impacts, and building health resilience. This NOSI encourages

applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the U.S. and globally. **Please refer to the Notice for additional information regarding specific requirements per NIH institution. Applicants must include NOT-ES-22-006 in Box 4B of the SF424 R&R form.** This notice applies to due dates through May 8, 2025.

NIH Funding Opportunities

Limited Submissions

Only one application per institution is allowed for the following FOAs and prior approval from the OVPR is required to be the sole applicant. If interested in applying, please provide the OVPR with notification 60 days prior to the deadline to ovpr.limitedsubmission@research.buffalo.edu before proceeding with the application.

NICDH Neonatal Research Network

[RFA-HD-23-001](#) (U24, Clinical Trial Optional) – **Data Coordinating Center**

[RFA-HD-23-002](#) (UG1, Clinical Trial Optional) – **Clinical Centers**

The NICHD invites institutions to submit applications to participate in the Neonatal Research Network (NRN). The purpose of the network is to improve healthcare and outcomes for newborns. The NRN consists of Clinical Centers (CC) with Neonatal Intensive Care Units and a Data Coordinating Center (DCC). The current network includes 15 CCs and one DCC.

The CC's specific objective is to develop and implement Network protocols, recruiting study participants, implementing study interventions, conducting required follow-up examinations, and working together to publish study results. The DCC's specific objective is to develop, implement, and analyze results for Network protocols, especially providing biostatistical expertise, computer programming, and project management to design protocols, develop statistical analysis plans, develop data management systems, manage Network study funds, monitor data integrity and study safety, and work with study investigators to analyze and publish study results. **Application Due Date:** August 11, 2022

NICHD Maternal-Fetal Medicine Units Network

[RFA-HD-23-017](#) (U24, Clinical Trial Optional) - **Data Coordinating Center**

[RFA-HD-23-016](#) (UG1, Clinical Trial Optional) – **Clinical Centers**

The purpose of the Maternal-Fetal Medicine Units Network (MFMU) is to improve obstetric care, pregnancy health, and outcomes for pregnant and lactating people and their babies. The MFMU Networks consists of perinatal Clinical Centers (CCs) and a Data Coordinating Center (DCC). The current MFMU network includes 12 CCs. The CC's specific objective is to develop and implement Network protocols, recruiting study participants, implementing study interventions, conducting required follow-up examinations, and working together to publish study results. The DCC's specific objective is to develop, implement, and analyze results for Network protocols, especially providing biostatistical expertise, computer programming, and project management to design protocols, develop statistical analysis plans, develop data management systems, manage Network study funds, monitor data integrity and study safety, and work with study investigators to analyze and publish study results. **Application Due Date:** August 11, 2022

NIH Funding Opportunities: Request for Applications (RFA)

AUGUST 2022 DUE DATES

[RFA-DA-23-052](#) (U24 Clinical Trial Not Allowed)

Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program

This FOA aims to support a single coordinating center (CC). The CC is charged with the task of enhancing collaborations and innovation in research to address NIH's high priority HIV research areas among the cohort investigators and other researchers engaged in the HIV and addiction research field by leveraging the rich data and biospecimen resources available through the cohorts program. The center coordinator(s) will lead the CC and is responsible for the overall performance of the project, including the development, tracking, and reporting of performance metrics by all the currently funded U01 cohort program sites. **Application Due Date:** August 11, 2022

[RFA-DA-23-009](#) (R21, Clinical Trial Not Allowed)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery

NIDA encourages exploratory and developmental research to better understand the role of social connectedness and/or loneliness in prevention, treatment and recovery from substance use disorders (SUDs).

Application Due Date: August 15, 2022

[RFA-DA-23-010](#) (R34, Clinical Trial Optional)

Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery

This FOA encourages pilot work and preliminary research to support preparation for large-scale, rigorous trials examining strategies to address social connectedness and/or loneliness in order to prevent or treat SUDs or enhance recovery. **Application Due Date:** August 15, 2022

[RFA-MD-22-009](#) (R01, Clinical Trial Required)

Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Geographic Hot Spots in the United States

This initiative will support research projects that examine innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subgroups within primary care settings located in geographic areas with a high rate of new infections in the United States.

Application Due Date: August 15, 2022

[RFA-RM-22-019](#) (DP2, Clinical Trial Optional)

NIH Director's New Innovator Award Program

The [New Innovator Award Program](#) supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. **Application Due Date:** August 19, 2022.

[RFA-DA-23-002](#) (R01, Clinical Trial Required)

Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users

This FOA supports research that addresses limitations in understanding how to ensure all people who use drugs and are at risk for, or living with, HIV have rapid access to high quality substance use disorder treatment and HIV care services, including Pre-exposure prophylaxis (PrEP).

Application Due Date: August 11, 2023

SEPTEMBER 2022 DUE DATES

[RFA-RM-22-021](#) (DP5 Early Independence Award)

NIH Director's Early Independence Awards

This award provides an opportunity for exceptional junior scientists to accelerate their entry into an independent research career by forgoing the traditional post-doctoral training period. The Early Independence Award is intended for select junior investigators, who have already established a record of scientific innovation and research productivity and have demonstrated unusual scientific vision and maturity.

Applications due by September 2, 2022

[RFA-RM-22-018](#) (DP1, Clinical Trial Optional)

NIH Director's Pioneer Award Program

The Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. **Application Due Date:** September 9, 2022

[RFA-CA-22-003](#) (R61, Clinical Trial Not Allowed)

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research

This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. **Application Due Date:** September 22, 2022

OCTOBER 2022 DUE DATES

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed

[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space. **Application Due Date:** October 11, 2022

[RFA-DK-22-003](#) (R01, Clinical Trial Optional)

Promoting Organ and Tissue Donation Among Health Disparity Populations

Proposed studies may include studying individual-level factors such as attitudes, beliefs, and behaviors towards organ and tissue donation, as well as the need for transplantation, among health disparity populations. In addition, proposed studies may examine the influence of SDoH on disparities in organ and tissue donation, including the impact of structural racism on donation.

Application Due Date: October 27, 2022

NOVEMBER 2022 DUE DATES

[RFA-MD-22-008](#) (R01, Clinical Trials Optional)

Understanding and Addressing Misinformation among Populations that Experience Health Disparities

This initiative seeks to stimulate multi-level research (see [NIMHD Research Framework](#)) to understand and mitigate the harmful impacts of misinformation and disinformation among populations that experience health disparities and to inform public health practice. Examples include COVID-19, HIV/AIDS, STIs, vaccines, genetic testing, cancer, and tobacco use and cessation, among others.

Application Due Date: November 13, 2022

[RFA-DA-23-015](#) (R01, Clinical Trial Not Allowed)

Transformative Research on the Basic Mechanisms of Polysubstance Use in Addiction

NIDA seeks to stimulate innovative research that will transform our understanding of the basic mechanisms that underlie polysubstance use in addiction. These studies will investigate novel neurobiological, pharmacological and/or behavioral mechanisms that drive the behavioral and pharmacological profiles observed following polysubstance use. **Application Due Date:** November 14, 2022

[RFA-AA-22-001](#) **Specialized Alcohol Research Centers** (P50, Clinical Trial Optional)

[RFA-AA-22-002](#) **Comprehensive Alcohol Research Centers** (P60, Clinical Trial Optional)

NIAAA supports a broad-based Alcohol Research Centers program to foster and conduct interdisciplinary, collaborative research on Alcohol Use Disorder (AUD), alcohol misuse and alcohol related problems, and other health related consequences across the lifespan. The Centers are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research. **Application Due Date:** November 15, 2022

[RFA-DA-23-011](#) (UM1 – Clinical Trial Optional)

Registry of Medical Cannabis Use and Health Outcomes

NIDA seeks applications to develop and maintain a medicinal cannabis use registry to assess the medical conditions reported as reasons for using medicinal cannabis, how and what products are being used, and the associated medical outcomes. The goal of this registry is to inform research, policy, and clinical recommendation practices on medicinal cannabis, associated conditions, and outcomes.

Application Due Date: November 16, 2022

NCI's Informatics Technology for Cancer Research Program FOAs (Clinical Trial Optional):

[RFA-CA-22-021](#) **Development of Innovative Informatics Methods and Algorithms** (R21)

[RFA-CA-22-022](#) **Early Stage Development of Informatics Technologies** (U01)

[RFA-CA-22-023](#) **Advanced Development of Informatics Technologies** (U24)

[RFA-CA-22-024](#) **Sustained Support for Informatics Technologies** (U24)

The program supports the development of critical tools and resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. **Application Due Date:** November 17, 2022

MULTIPLE DUE DATES

[RFA-HL-22-010](#) (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) (K01 Independent Clinical Trial Not Allowed)

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: October 13, 2022; February 14, 2023; October 13, 2023; February 13, 2024

[RFA-HL-23-018](#) (R21)

Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at www.biolincc.nhlbi.nih.gov.

Application Due Dates: October 19, 2022; June 20, 2023; October 19, 2023; June 20, 2024; October 21, 2024.

[RFA-MH-22-140](#) (R01); [RFA-MH-22-141](#) (R21) – Clinical Trial Not Allowed

Understanding Suicide Risk and Protective Factors among Black Youth

These FOAs encourage research that is designed to identify neurobiological, behavioral, social, and structural/systemic mechanisms underlying risk and protective factors for suicide among Black youth, with consideration for identification of novel targets for future development of prevention and intervention efforts.

Application Due Dates: October 19, 2022; June 20, 2023

[RFA-EB-21-001](#) (R01, Clinical Trial Optional)

Technology Development to Reduce Health Disparities

This announcement encourages applications to develop medical devices, imaging systems, robotic systems, biomaterial interfaces, synthetic biological systems, mathematical and modeling solutions, and other technologies to address the healthcare needs of populations that experience health disparities.

Application Due Dates: January 26, 2023; January 26, 2024

[RFA-HL-23-004](#) (R35, Clinical Trial Optional)

NHLBI Outstanding Investigator Award (OIA)

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-HL-23-005](#) (R35, Clinical Trial Optional)

NHLBI Emerging Investigator Award (EIA)

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/PIs on at least two NHLBI R01-equivalent awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. **Application Due Dates:** February 15, 2023; February 15, 2024

[RFA-DA-22-037](#) (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) (R21, Clinical Trial Optional)

Accelerating the Pace of Drug Abuse Research Using Existing Data

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.

Application Receipt Dates: Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-22-040](#) (R01, Clinical Trial Optional)

High Priority HIV and Substance Use Research

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD).

Application Due Dates: Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-DA-23-008](#) (R61/R33, Clinical Trial Required)

Stimulants and HIV: Addressing Contemporary and Recurring Epidemics

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs.

Application Due Dates: Multiple Dates; see announcement. **Expiration Date:** November 13, 2024

[RFA-DA-23-021](#) (R43/R44, Clinical Trial Optional)

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device.

Application Due Dates: Multiple Dates; see announcement. **Expiration Date:** February 15, 2025

NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)

[PAR-22-151](#) (D43, Clinical Trial Optional)

Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions

This FOA can support training for conducting research in a broad range of HIV research areas across HIV prevention, treatment, care, and quality of life continuum. An application should focus the proposed training program to strengthen research capacity in a defined high priority HIV scientific area aligned with NIH HIV/AIDS research priorities at a specific LMIC institution and collaborating LMIC partner institutions.

Application Due Dates: August 22, 2022; August 22, 2023; August 22, 2024

R50, Clinical Trial Not Allowed

[PAR-22-187](#) - **NCI Research Specialist (Laboratory-based Scientist)**

[PAR-22-188](#) – **NCI Research Specialist (Core-based Scientist)**

NCI invites applications in any area of NCI-funded cancer research. The Awards are designed to encourage the development of stable research career opportunities for exceptional scientists who want to contribute to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators.

[PAR-22-186](#) – (R21 Clinical Trial Not Allowed)

Transgender People: Immunity, Prevention, and Treatment of HIV and STIs

This FOA is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical)

used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI). **Application Due Dates:** December 7, 2022; December 7, 2023; December 7, 2024

[PAR-22-162](#) (U01, Clinical Trial Not Allowed)

Research Opportunities in Established Cancer Epidemiology Cohort Studies

NCI will support research in established cancer epidemiology cohort studies, defined as studies that have achieved their initial planned recruitment goal. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum.

Application Due Dates: Multiple dates; see announcement. **Expiration Date:** March 2, 2025

[PAR-22-180](#) (R35, Clinical Trial Optional)

Maximizing Investigators' Research Award

This program provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. This FOA allows applications from eligible NIGMS-funded investigators and from New Investigators proposing research within the scientific mission of the NIGMS.

Application Due Dates: Multiple dates; see announcement. **Expiration Date:** May 17, 2025

[PAR-22-164](#) (R01, Clinical Trial Optional)

[PAR-22-165](#) (R21, Clinical Trial Optional)

Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem

NCI, a primary funder of cancer-related behavioral research, seeks to continue support for the use and integration of non-traditional data collection and analytic techniques in cancer communication science. This FOA is intended to encourage research projects in three distinct domains related to cancer communication: 1) Utility and application of new cancer communication surveillance approaches; 2) Development and testing of rapid cancer communication interventions using innovative methods and designs; 3) Development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels.

Application Due Dates: Multiple dates; see announcement. **Expiration Date:** September 8, 2025

NIH Funding Opportunities: Program Announcements (PA)

[PA-22-176](#) (R43/R44, Clinical Trial Not Allowed) – Phase I

[PA-22-177](#) (R43/R44, Clinical Trial Not Allowed) – Phase II

Omnibus Solicitation for Small Business Innovation Research Grant Applications

Application Due Dates: September 5, 2022; January 5, 2023; April 5, 2023

[PA-22-178](#) (R41/R44, Clinical Trial Required) - Phase I, Phase II, and Fast Track

[PA-22-179](#) (R41/R44, Clinical Trial Required) - Phase I, Phase II, and Fast Track

Omnibus Solicitation for Small Business Technology Transfer Grant Applications

Application Due Dates: September 5, 2022; January 5, 2023; April 5, 2023

University at Buffalo Funding Opportunities

VPRED Equipment Programs

The Vice President for Research and Economic Development is sponsoring two new programs:

Matching Program for Equipment Purchases

The program will distribute up to \$1,000,000/year as matching funds, at a 1:1 ratio with funds provided by faculty, departments, or units. Up to \$100,000 will be provided by the VPRED for qualifying purchases. UB faculty members are invited to submit proposals, which will be reviewed on a rolling basis. Proposals must include the following elements:

1. Name & Contact Information for the PI
2. Make & Model of the Equipment
3. Purchase price (with attachment of a current price quotation)
4. List of faculty who will use the equipment
5. Proposed location for placement of the new equipment
6. Proposal Narrative, including description of Impact, Scope and plans for Maintenance and

Sharing.

- The Impact section should include specific plans for the use of the equipment (e.g., providing an overview of the application of the equipment to collect key data for projects under investigation by each faculty member listed).
- Specific plans for submission of grant proposals should be detailed

Proposals may be submitted between June 1, 2022 – April 30, 2024 via email to the Executive Director for Research Initiatives (EDRI@buffalo.edu).

Program for Equipment Maintenance

The program will distribute up to \$500,000 as matching funds, at a 1:1 ration with funds provided by faculty, departments, or units.

Proposals must include the following elements:

1. Name & Contact Information for the PI
2. Make & Model of the Equipment
3. Purchase Price and Purchase Date
4. List of faculty who use the equipment
5. Location of the instrument
6. Proposal Narrative, including a description of projects and grant applications that are dependent on access to the instrument.

Proposals may be submitted between June 1, 2022 – April 30, 2024 via email to the Executive Director for Research Initiatives (EDRI@buffalo.edu).

OVPRED Planning Grants to Support Multi-Institutional Grant Applications

[Planning Grants](#) of up to \$2,000 are available to support the submission of multi-institutional applications for extramural support. Funds may be used to support travel and meeting costs associated with planning extramural applications. Funds may not be used to support purchase of research supplies or personnel costs. Proposals (2 pgs max) should include the following:

1. Title and Brief Description of the proposed inter-institutional grant application
2. List of participating institutions and faculty
3. Total request for support for planning grant expenses
4. Targeted funding agency for extramural proposal
5. Outline of proposed budget for extramural application

Applications will be accepted and reviewed on a rolling basis. Proposals may be submitted as one PDF to fundingopps@research.buffalo.edu

Individual Actions for Sustainability



Pay Attention to Labels: Buy organic food whenever possible. Choose Fair Trade certified goods to support companies dedicated to sustainable production and paying laborers a fair wage. If a coffee drinker, look for “shade-grown”, which is grown while keeping forest habitats intact for migratory birds and other species.

For more information on RAS services, visit our website at sphhp.buffalo.edu/ras